Axsome Therapeutics, Inc. (AXSM) Guidance & Earnings Results
On 2026-08-10 Axsome Therapeutics, Inc. reaffirmed guidance: "Cash sufficient to fund operations into cash flow…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AXSMAxsome Therapeutics, Inc.Follow AXSM — free
—
Price chart with a free account
- Market cap
- 7.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 10 Aug 26 | Reaffirmed | Cash sufficient to fund operations into cash flow positivity |
| 23 Feb 26 | Reaffirmed | Strong revenue growth and narrowing losses |
| 4 Aug 25 | Reaffirmed | Cash sufficient to fund operations into cash flow positivity. |
Axsome Therapeutics, Inc. — questions
- What guidance did Axsome Therapeutics, Inc. give?
- On 2026-08-10: "Cash sufficient to fund operations into cash flow positivity"
- When does Axsome Therapeutics, Inc. report earnings?
- Axsome Therapeutics, Inc.'s next earnings report is expected on 2026-11-02.
Every figure on this page comes from Axsome Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.